Safety Panel Warns NASA Over Commercial Launchers
In the next couple weeks the Obama administration will make a decision on the future of U.S. human spaceflight. Now, the Aerospace Safety Advisory Panel (ASAP), an independent panel that has been evaluating NASA’s safety performance and advising the agency since 1968, has published its annual report, which questions the safety of using commercial launch vehicles to put astronauts in space.
In 2009, an independent committee, the Augustine Panel, was commissioned to review the current U.S. human spaceflight program and to provide recommendations to the administration. The panel’s final report implied that NASA should abandon its new rocket, Ares I, which is being built to ferry astronauts into orbit after the space shuttles retire. Instead, the panel said NASA should rely on the commercial sector to carry both crew and cargo into low Earth orbit.
ASAP states that NASA’s program for the development of commercial systems, called Commercial Orbital Transportation Services (COTS), is absent of a human-rating process. So far, the agency has only awarded contracts to two companies, SpaceX and Orbital Sciences, for the development of systems to carry cargo. ASAP is also concerned about NASA’s lack of assessing the safety of these systems.
According to the ASAP report, “switching from a well-designed, safety-optimized system to commercially-developed vehicles based on nothing more than unsubstantiated claims would seem a poor choice. Before any change is made to another architecture, the inherent safety of that approach must be assessed to ensure that it offers a level of safety equal to or greater than the program of record.”
The inside story of how ChatGPT was built from the people who made it
Exclusive conversations that take us behind the scenes of a cultural phenomenon.
How Rust went from a side project to the world’s most-loved programming language
For decades, coders wrote critical systems in C and C++. Now they turn to Rust.
Design thinking was supposed to fix the world. Where did it go wrong?
An approach that promised to democratize design may have done the opposite.
Sam Altman invested $180 million into a company trying to delay death
Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.